64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention

Epidemiology, Screening & The Spectrum of Alcohol Use

Alcohol misuse represents the third leading preventable cause of death in the United States, responsible for over 140,000 deaths annually and contributing substantially to cardiovascular disease, liver cirrhosis, pancreatitis, neurocognitive decline, trauma, and oncologic malignancies (particularly head and neck, esophageal, colorectal, and breast cancers).

Universal Screening Guidelines

The United States Preventive Services Task Force (USPSTF) assigns a Grade B recommendation to screening for unhealthy alcohol use in all primary care adults aged 18 years and older, including pregnant individuals, followed by providing those engaged in risky drinking with brief behavioral counseling interventions.

Validated primary care screening modalities include:

1. AUDIT-C (Alcohol Use Disorders Identification Test - Consumption): A 3-item self-report questionnaire assessing drinking frequency, typical quantity, and frequency of heavy episodic bingeing. Each item is scored 0 to 4 points (total 0–12 points):
   • Positive Screen for Hazardous Drinking: Score $\ge 4$ in adult men; score $\ge 3$ in adult women and all adults aged $\ge 65$ years.
   • Offers high diagnostic sensitivity (86%) and specificity (89%) for detecting the spectrum of unhealthy alcohol use.
2. Single-Question Alcohol Screen (National Institute on Alcohol Abuse and Alcoholism [NIAAA]):
   • Prompt: "How many times in the past year have you had 5 (for men) or 4 (for women) or more drinks in a single day?"
   • Positive Screen: Any response $\ge 1$ episode is considered positive (sensitivity and specificity $>80%$) and warrants a comprehensive clinical evaluation.
3. Full 10-Item AUDIT: Developed by the World Health Organization (WHO), evaluating consumption, dependence symptoms, and alcohol-related harms (scores 8–15 indicate hazardous/harmful use; $\ge 16$ indicates severe dependence).
4. CAGE Questionnaire: An older 4-item mnemonic (Cut down, Annoyed, Guilty, Eye-opener). While historical, the USPSTF notes CAGE lacks sensitivity for identifying the full continuum of hazardous drinking because it detects primarily late-stage, severe dependence; AUDIT-C is preferred.

Standard Drink Quantitation & Consumption Thresholds

Accurate clinical assessment requires quantitating alcohol consumption in terms of standard drink equivalents. In the United States, one standard drink is defined as containing 14.0 grams (0.6 fluid ounces) of pure ethanol:

• 12 fluid ounces of regular beer (approximately $5%$ alcohol by volume [ABV]).
• 5 fluid ounces of table wine (approximately $12%$ ABV).
• 1.5 fluid ounces (one shot) of 80-proof distilled spirits (approximately $40%$ ABV; e.g., vodka, gin, whiskey, rum).

                     DEFINITIONS OF DRINKING PATTERNS (NIAAA / CDC)

   Pattern               Operational Definition (Standard Drinks)                Clinical Significance
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Moderate Drinking     • Men: ≤ 2 drinks per day                               Upper limit of dietary guidelines;
                         • Women: ≤ 1 drink per day                              no health benefits in young adults.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Binge Drinking        • Men: ≥ 5 drinks on a single occasion (~2 hours)       Brings Blood Alcohol Concentration
   (Episodic Heavy)      • Women: ≥ 4 drinks on a single occasion (~2 hours)     (BAC) to ≥ 0.08 g/dL (17.4 mmol/L);
                                                                                 drives acute trauma and arrhythmias.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Heavy Drinking        • Men: ≥ 15 drinks per week                             Significantly increases risk of
   (Chronic Excessive)   • Women: ≥ 8 drinks per week                            alcoholic liver disease, cardiomyopathy,
                         (or any binge drinking on ≥ 5 days in a month)          hypertension, and malignancy.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

---

Diagnostic Criteria: DSM-5 Alcohol Use Disorder

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), integrates the prior separate categories of "alcohol abuse" and "alcohol dependence" into a single diagnostic continuum termed Alcohol Use Disorder (AUD). A problematic pattern of alcohol use leading to clinically significant impairment or distress is defined by the presence of at least 2 of 11 criteria occurring within a 12-month period across four behavioral domains:

                         THE 11 DSM-5 CRITERIA FOR ALCOHOL USE DISORDER

   Domain                  DSM-5 Criterion Description
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Impaired Control        1. Alcohol consumed in larger amounts or over a longer period than intended.
                           2. Persistent desire or unsuccessful efforts to cut down or control alcohol use.
                           3. Great deal of time spent in activities necessary to obtain, use, or recover.
                           4. Craving, or a strong desire or urge to use alcohol.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Social Impairment       5. Recurrent alcohol use resulting in failure to fulfill major role obligations
                              at work, school, or home.
                           6. Continued alcohol use despite persistent or recurrent social/interpersonal problems.
                           7. Important social, occupational, or recreational activities given up or reduced.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Risky Use               8. Recurrent alcohol use in situations in which it is physically hazardous (e.g., driving).
                           9. Continued alcohol use despite knowledge of having a persistent or recurrent physical
                              or psychological problem caused or exacerbated by alcohol.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Pharmacological        10. Tolerance, defined by either:
                              a) Need for markedly increased amounts of alcohol to achieve intoxication/desired effect.
                              b) Markedly diminished effect with continued use of the same amount of alcohol.
                          11. Withdrawal, manifested by either:
                              a) Characteristic withdrawal syndrome for alcohol.
                              b) Alcohol (or a closely related substance, such as a benzodiazepine) is taken to
                                 relieve or avoid withdrawal symptoms.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Severity Stratification

Severity is categorized according to the absolute number of diagnostic criteria met:

• Mild AUD: 2 to 3 criteria present.
• Moderate AUD: 4 to 5 criteria present.
• Severe AUD: $\ge 6$ criteria present.

Diagnostic Nuance: Neither tolerance nor withdrawal is strictly required to establish a diagnosis of AUD if sufficient psychosocial and behavioral criteria are met. Furthermore, tolerance and withdrawal developed during medically supervised treatment with prescription medications (e.g., benzodiazepines) do not count toward criteria 10 and 11.

---

Neurobiology & Acute Alcohol Withdrawal Syndrome

Neurochemical Pathophysiology

Ethanol is a central nervous system depressant with dual primary molecular targets:

1. $\text{GABA}_\text{A}$ Receptor Potentiation: Ethanol acts as a positive allosteric modulator at inhibitory gamma-aminobutyric acid type A ($\text{GABA}_\text{A}$) receptors, increasing chloride ion influx, hyperpolarizing neuronal membranes, and dampening CNS excitability.
2. NMDA Receptor Inhibition: Ethanol non-competitively antagonizes excitatory N-methyl-D-aspartate (NMDA) glutamate receptors, suppressing excitatory glutamatergic neurotransmission.

With chronic, heavy ethanol exposure, homeostatic neuroadaptation occurs:

• Downregulation and desensitization of $\text{GABA}_\text{A}$ receptors.
• Upregulation of NMDA glutamate receptors and voltage-gated L-type calcium channels.

When ethanol is abruptly removed or rapidly cleared from the circulation, this adaptive neurochemical balance collapses: the loss of inhibitory GABAergic tone unmasks massive, unopposed excitatory glutamatergic neurotransmission and central noradrenergic hyperactivity (excess locus coeruleus firing). This hyperadrenergic state drives the clinical manifestations of acute alcohol withdrawal syndrome (AWS).

                      TIMELINE OF ACUTE ALCOHOL WITHDRAWAL MANIFESTATIONS

   Hours Post-Cessation    Clinical Manifestations                           Features & Differential Clues
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   6 to 12 Hours           Minor Withdrawal Syndrome                         Tremor, anxiety, diaphoresis, insomnia,
                           • Autonomic hyperactivity                         tachycardia (HR > 100), hypertension,
                           • Gastrointestinal distress                       nausea, vomiting; SENSORIUM IS INTACT.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   12 to 48 Hours          Alcoholic Hallucinosis                            Auditory, visual, or tactile perceptions;
                           (Occurs in ~10-25% of severe AWS)                 PATIENT REMAINS FULLY ORIENTED with clear
                                                                             sensorium and intact insight.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   24 to 48 Hours          Withdrawal Seizures                               Generalized tonic-clonic, brief, single
                           ("Rum Fits")                                      or short burst; normal post-ictal EEG;
                                                                             treat with IV benzos (NOT phenytoin!).
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   48 to 96 Hours          DELIRIUM TREMENS (DTs)                            Profound fluctuating delirium, global confusion,
   (Peak at 72-96h)        • Severe autonomic instability                    extreme agitation, visual/tactile hallucinations,
                           • Hyperpyrexia, drenching sweats                  fever (> 38.3°C), marked tachycardia (> 120),
                           • Life-threatening medical crisis                 hypertension. MORTALITY RATE UP TO 5%.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Delirium Tremens vs. Alcoholic Hallucinosis

A cardinal board-exam distinction is differentiating Alcoholic Hallucinosis from Delirium Tremens:

• Alcoholic Hallucinosis develops within 12–24 hours, features vivid sensory illusions (e.g., hearing voices, seeing insects), but the patient's cognitive sensorium remains entirely clear (oriented to person, place, and time with normal vital signs or mild tachycardia).
• Delirium Tremens (DTs) emerges later (48–96 hours) and is defined by clouding of consciousness, disorientation, severe fluctuating delirium, and violent autonomic storm (hyperthermia, diaphoresis, malignant hypertension, marked tachycardia). DTs represents an intensive care medical emergency requiring high-dose intravenous benzodiazepines, fluid resuscitation, electrolyte repletion, and hemodynamic monitoring.

Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar)

The CIWA-Ar is a validated 10-item instrument used to quantify withdrawal severity and titrate pharmacotherapy:

• Scores range from 0 to 67 points.
• Evaluates: Nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache/fullness in head, and orientation/clouding of sensorium.
• Score $< 8$: Mild withdrawal; generally managed with supportive care without medications.
• Score 8 to 14: Moderate withdrawal; warrants initiation of pharmacotherapy.
• Score $\ge 15$: Severe withdrawal; high risk for seizures and progression to DTs; mandates aggressive pharmacotherapy.

Inpatient Pharmacotherapy: Symptom-Triggered Benzodiazepine Protocols

Symptom-triggered therapy (administering medication only when CIWA-Ar $\ge 8-10$) is proven superior to fixed-schedule dosing, achieving shorter treatment duration, lower cumulative benzodiazepine exposure, and lower rates of oversedation.

Benzodiazepine Selection Based on Hepatic Function:

• Intact Hepatic Function: Long-acting agents such as diazepam (5–10 mg IV/PO) or chlordiazepoxide (25–50 mg PO) provide smooth, sustained self-tapering protection against breakthrough seizures and delirium due to their long elimination half-lives and active metabolites (e.g., desmethyldiazepam).
• Hepatic Impairment / Advanced Cirrhosis / Acute Hepatitis: Long-acting agents undergo hepatic cytochrome P450 oxidation (Phase I metabolism), which is markedly impaired in cirrhosis, leading to toxic drug accumulation, profound oversedation, respiratory depression, and precipitation of hepatic encephalopathy.
  • The Clinical Rule: Use the "LOT" drugs—Lorazepam, Oxazepam, and Temazepam.
  • These agents bypass Phase I oxidation and undergo direct Phase II glucuronidation, which is preserved even in end-stage liver disease. They possess no active metabolites.
  • Preferred Regimen in Liver Disease: Lorazepam 1 to 2 mg PO/IV or Oxazepam 15 to 30 mg PO every 1 to 2 hours titrated to CIWA-Ar $<8-10$.

Wernicke-Korsakoff Syndrome & The Thiamine Mandate

Chronic alcohol misuse impairs gastrointestinal thiamine (Vitamin $B_1$) absorption, decreases hepatic thiamine storage, and reduces cellular utilization via thiamine pyrophosphokinase inhibition. Thiamine is an obligate cofactor for key carbohydrate metabolic enzymes: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase.

• Wernicke Encephalopathy: Acute, reversible neuropsychiatric syndrome characterized by the classic clinical triad:
  1. Encephalopathy / Acute Confusion (82% of cases): Profound disorientation, inattention, apathy.
  2. Oculomotor Dysfunction (29% of cases): Bilateral abducens (CN VI) nerve palsy, horizontal/vertical nystagmus, conjugate gaze palsy.
  3. Gait Ataxia (23% of cases): Vestibular dysfunction and cerebellar vermis atrophy producing a broad-based, unsteady gait.
  • Note: Less than one-third of patients exhibit the complete triad; any unexplained confusion, ataxia, or ophthalmoplegia in a malnourished or alcohol-dependent patient mandates presumptive treatment.
• Korsakoff Syndrome: Chronic, irreversible neurocognitive sequela resulting from structural necrosis of the mammillary bodies and dorsomedial thalamic nuclei. Characterized by severe anterograde and retrograde amnesia with confabulation (fabrication of memories without conscious intent to deceive) and lack of insight.

[!CRITICAL] Parenteral Thiamine Before Glucose Always administer high-dose parenteral thiamine (500 mg IV TID for 2 to 3 days, followed by 250 mg IV daily) BEFORE or SIMULTANEOUSLY WITH intravenous glucose or dextrose-containing fluids. Administering glucose to a thiamine-deficient patient accelerates aerobic glycolysis, rapidly consuming residual thiamine stores and precipitating acute, fatal Wernicke encephalopathy and brainstem herniation.

---

Evidence-Based Pharmacotherapy for AUD Maintenance & Relapse Prevention

Following successful acute detoxification, pharmacotherapy should be offered to all patients with moderate-to-severe AUD to promote abstinence or reduce heavy drinking days. The American Psychiatric Association (APA) and Substance Abuse and Mental Health Services Administration (SAMHSA) recommend naltrexone or acamprosate as first-line agents.

                  COMPARISON OF PHARMACOTHERAPIES FOR ALCOHOL USE DISORDER

   Medication          Mechanism of Action           Dosing & Formulation        Key Indications & Advantages      Strict Contraindications & Risks
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Naltrexone          Mu-opioid receptor            • Oral: 50 mg PO daily      First-line; dampens euphoria      • ACTIVE OPIOID USE / DEPENDENCE
   (Oral: Revia;       antagonist; blocks            • IM (Vivitrol): 380 mg     and craving; reduces heavy        (requires 7–14 day washout;
   IM: Vivitrol)       endogenous β-endorphin        gluteal injection every     drinking days; CAN BE STARTED     precipitates acute withdrawal!)
                       reward pathways               4 weeks                     WHILE PATIENT IS STILL DRINKING.  • Acute hepatitis or liver failure.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Acamprosate         NMDA receptor antagonist;     • 666 mg PO three times     First-line; RESTORES GLUTAMATE/   • SEVERE RENAL IMPAIRMENT
   (Campral)           GABA-A receptor agonist;      daily (two 333 mg           GABA BALANCE; superior for        (CrCl < 30 mL/min contraindicated;
                       modulates post-cessation      delayed-release tablets     MAINTAINING COMPLETE ABSTINENCE;  dose-reduce to 333 mg TID if
                       hyperglutamatergic tone       TID)                        SAFE IN ADVANCED CIRRHOSIS/LIVER. CrCl 30–50 mL/min).
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Disulfiram          Irreversible aldehyde         • 250 to 500 mg PO          Aversion / deterrent therapy;     • Severe coronary artery disease
   (Antabuse)          dehydrogenase (ALDH)          once daily                  requires highly motivated         • Psychosis; pregnancy
                       inhibitor; triggers toxic                                 patient or DIRECTLY OBSERVED      • Concomitant metronidazole
                       acetaldehyde buildup                                      DAILY ADMINISTRATION.             • Severe baseline hepatic disease.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Gabapentin          Voltage-gated calcium         • 300 mg TID titrated to    Off-label; treats protracted      • Dose-dependent sedation
   (Neurontin)         channel α2-δ ligand;          900–1800 mg/day in          withdrawal, insomnia, and         • Abuse liability (Schedule V
                       indirect GABA enhancement     divided doses               dysphoric craving; SAFE IN LIVER. in some states); renal adjustment.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Topiramate          AMPA/kainate antagonist;      • 25 mg daily titrated to   Off-label; reduces heavy          • Cognitive slowing ("Dopamax")
   (Topamax)           carbonic anhydrase inhibitor; 100–300 mg/day in           drinking and craving; promotes    • Paresthesias; nephrolithiasis
                       facilitates GABA release      divided doses               concomitant weight loss.          • Glaucoma; teratogenic (cleft lip).
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Naltrexone (Revia, Vivitrol)

• Mechanism: Naltrexone is a competitive antagonist at mu-opioid receptors. In alcohol consumption, ethanol stimulates the release of endogenous beta-endorphins that bind mu receptors in the ventral tegmental area (VTA), disinhibiting dopamine release in the nucleus accumbens. By blocking mu receptors, naltrexone attenuates the dopaminergic "high" and hedonic reinforcement of alcohol, breaking the positive-reinforcement cycle and reducing heavy drinking days.
• Initiation Pearl: Patients do NOT need to be abstinent prior to starting naltrexone. It can be initiated while the patient is still actively drinking to help reduce consumption.
• Formulations:
  • Oral: 50 mg once daily (start at 25 mg daily for 2–3 days to minimize initial gastrointestinal side effects).
  • Intramuscular Depot (Vivitrol): 380 mg administered as a deep intramuscular gluteal injection every 4 weeks. Vivitrol bypasses daily oral adherence barriers and provides sustained therapeutic drug levels.
• Adverse Effects: Nausea, abdominal pain, headache, dizziness, fatigue, and dose-dependent hepatotoxicity at supra-therapeutic doses.
• Strict Contraindications:
  1. Concurrent Opioid Analgesic Therapy or Opioid Use Disorder: Naltrexone will immediately displace full and partial agonists, precipitating severe, acute opioid withdrawal. Patients must be completely opioid-free for at least 7 to 10 days for short-acting opioids and 14 days for buprenorphine or methadone before initiation.
  2. Acute Hepatitis or Acute Hepatic Failure: While stable, mild-to-moderate chronic cirrhosis is not an absolute contraindication, naltrexone should be avoided in acute hepatic necrosis, acute alcoholic hepatitis, or decompensated liver failure with jaundice.

2. Acamprosate (Campral)

• Mechanism: Chronic ethanol consumption creates an up-regulated glutamatergic excitatory state. Acamprosate (calcium acetylhomotaurinate) structurally resembles GABA and taurine. It acts as a functional glutamate NMDA receptor antagonist and a modulator of $\text{GABA}_\text{A}$ receptors, dampening post-detoxification "hyper-glutamatergic tone" ("putting out the neurochemical fire"). This reduces protracted withdrawal symptoms, restlessness, and negative-reinforcement craving.
• Efficacy: Acamprosate is most effective for sustaining complete abstinence in patients who have already achieved detoxification. It does not mitigate the acute reinforcing effects if alcohol is consumed.
• Dosing: 666 mg PO three times daily (administered as two 333 mg tablets TID). The frequent TID dosing represents a common barrier to long-term medication adherence.
• Elimination & Organ Safety:
  • Hepatic: Acamprosate is not metabolized by the liver and does not interact with cytochrome P450 enzymes. It is completely safe in patients with severe hepatic disease, non-alcoholic fatty liver disease, and advanced alcoholic cirrhosis.
  • Renal: Acamprosate is excreted 100% unchanged by the kidneys.
  • Renal Dosing Guidelines:
    • $\text{CrCl} > 50\text{ mL/min}$: Full dose (666 mg TID).
    • $\text{CrCl } 30-50\text{ mL/min}$: Dose reduction to 333 mg TID.
    • $\text{CrCl} < 30\text{ mL/min}$: STRICTLY CONTRAINDICATED due to dangerous drug accumulation.

3. Disulfiram (Antabuse)

• Mechanism: Disulfiram is an irreversible inhibitor of aldehyde dehydrogenase (ALDH), the enzyme responsible for converting acetaldehyde (a toxic intermediate of ethanol oxidation) into acetate. Ingestion of even minor amounts of alcohol causes blood acetaldehyde levels to surge 5- to 10-fold within 10 to 30 minutes.
• The Disulfiram-Ethanol Reaction: Acetaldehyde accumulation induces severe, distressing, and potentially dangerous physiological symptoms: facial flushing, throbbing headache, diaphoresis, nausea, intractable vomiting, tachycardia, palpitations, dyspnea, and hypotension. The reaction lasts 30 to 120 minutes.
• Clinical Role & Limitations: Disulfiram acts purely as a psychological deterrent. It does not reduce physiological cravings or modulate reward circuits. Randomized clinical trials show that unmonitored disulfiram is no more effective than placebo due to poor treatment adherence (patients simply stop taking the pill when they plan to drink). It is effective only when administered under direct daily supervision (by a spouse, clinic nurse, or parole officer) in highly motivated patients.
• Contraindications: Severe coronary artery disease, congestive heart failure, history of stroke, psychosis, cognitive impairment, pregnancy, and concurrent use of metronidazole (compounds ALDH inhibition, risking acute delirium). Patients must avoid hidden alcohol sources (cough syrups, aftershave lotions, vinegar, mouthwashes).

4. Second-Line & Off-Label Pharmacotherapies

• Gabapentin: Administered at doses of 900 to 1800 mg/day in divided doses. By binding the $\alpha_2\text{-}\delta$ subunit of voltage-gated calcium channels, gabapentin reduces excitatory neurotransmission. It alleviates protracted subacute withdrawal symptoms: insomnia, anxiety, dysphoria, and craving. Because it undergoes zero hepatic metabolism and is excreted renally, gabapentin is an outstanding option for patients with alcoholic cirrhosis or elevated liver transaminases.
• Topiramate: Administered at 100 to 300 mg/day. Facilitates GABA transmission while antagonizing kainate/AMPA glutamate receptors. Reduces heavy drinking and craving. Side effects include psychomotor slowing ("dopamax"), paresthesias, metabolic acidosis, anorexia/weight loss, and nephrolithiasis.

---

Psychosocial Modalities in Longitudinal Care

Pharmacotherapy demonstrates the highest efficacy when integrated with structured evidence-based psychosocial interventions:

1. Motivational Interviewing (MI) & The FRAMES Approach:
   • Feedback on personal risk and current health status.
   • Responsibility placed on the patient for personal change.
   • Advice to change delivered clearly and nonjudgmentally.
   • Menu of alternative options and strategies.
   • Empathy emphasized throughout the encounter.
   • Self-efficacy supported and reinforced.
2. Cognitive Behavioral Therapy (CBT): Identifies conditioned internal and external environmental triggers, restructures distorted cognitive patterns surrounding drinking, and develops behavioral coping skills to manage high-risk relapse scenarios.
3. 12-Step Mutual-Aid Fellowships (Alcoholics Anonymous [AA]): A free, globally accessible, spiritually based, peer-led fellowship providing 24/7 social accountability, sponsorship, and structured behavioral steps toward maintaining continuous sobriety.